CSTL

Castle Biosciences Inc

Sep 18 • 04:00PM ET

23.46

+1.64 7.52 %

Healthcare • Diagnostics & Research • USA • NASD

Peers: GH EXAS FLGT CDNA MYGN NTRA QDEL DGX ILMN TXG

| Held by: VTI IWM VXF IWN DFAT IBB VTWO SCHA BSVO VHT

Index	RUT	P/E	-	EPS (ttm)	-0.36	Insider Own	2.87%	Shs Outstand	28.98M	Perf Week	3.12%
Market Cap	680.53M	Forward P/E	-	EPS next Y	-1.86	Insider Trans	-12.22%	Shs Float	28.17M	Perf Month	17.89%
Enterprise Value	441.95M	PEG	-	EPS next Q	-0.53	Inst Own	91.79%	Short Float	5.39%	Perf Quarter	24.06%
Income	-9.47M	P/S	1.97	EPS this Y	-394.47%	Inst Trans	1.72%	Short Ratio	2.96	Perf Half Y	14.22%
Sales	346.27M	P/B	1.49	EPS next Y	-1.74%	ROA	-1.83%	Short Interest	1.52M	Perf YTD	-11.97%
Book/sh	15.71	P/C	2.47	EPS next 5Y	-	ROE	-2.15%	52W High	35.84 -34.54%	Perf Year	-24.20%
Cash/sh	9.51	P/FCF	16.51	EPS past 3/5Y	- -	ROIC	-1.93%	52W Low	14.59 60.80%	Perf 3Y	-16.93%
Dividend Est.	-	EV/EBITDA	22.73	Sales past 3/5Y	52.25% 44.97%	Gross Margin	69.73%	Volatility	5.03% 4.88%	Perf 5Y	-51.73%
Dividend TTM	-	EV/Sales	1.28	EPS Y/Y TTM	-165.41%	Oper. Margin	-6.66%	ATR (14)	1.08	Perf 10Y	-
Dividend Ex-Date	-	Quick Ratio	6.69	Sales Y/Y TTM	20.40%	Profit Margin	-2.73%	RSI (14)	60.48	Recom	1.12
Dividend Gr. 3/5Y	- -	Current Ratio	6.85	EPS Q/Q	-50.68%	SMA20	4.03%	Beta	1.14	Target Price	35.62
Payout	0.00%	Debt/Eq	0.08	Sales Q/Q	-0.94%	SMA50	17.92%	Rel Volume	1.09	Prev Close	21.82
Employees	761	LT Debt/Eq	0.07	Earnings	Aug 04 AMC	SMA200	7.02%	Avg Volume	512.33K	Price	23.46
IPO	Jul 25, 2019	Option/Short	Yes / Yes	EPS/Sales Surpr.	128.24% 20.62%	Trades		Volume	558,785	Change	7.52%

Date	Action	Analyst	Rating Change	Price Target Change
Dec-14-23	Initiated	Guggenheim	Buy	$25
Jan-05-23	Initiated	Scotiabank	Sector Outperform	$54
Jan-07-22	Initiated	Stephens	Overweight	$59
Apr-30-21	Initiated	Lake Street	Buy	$94
Nov-10-20	Initiated	KeyBanc Capital Markets	Overweight	$70
Dec-27-19	Reiterated	Canaccord Genuity	Buy	$34 → $35
Aug-19-19	Initiated	SVB Leerink	Outperform	$28
Aug-19-19	Initiated	Robert W. Baird	Outperform	$27
Aug-19-19	Initiated	Canaccord Genuity	Buy	$26
Aug-19-19	Initiated	BTIG Research	Buy	$25

Sep-17-25 07:00AM	Castle Biosciences Named One of Newsweek's America's Greatest Companies 2025 (GlobeNewswire)
Sep-09-25 07:00AM	New Data at American Foregut Society's 2025 Annual Meeting Demonstrates TissueCypher Can Detect High-Risk Barrett's Esophagus Patients Not Identified by Pathology to Support Improved Care Decisions (GlobeNewswire)
Aug-28-25 10:44AM	FDA Tightens Survival Standards as Cancer Drug Pipeline Hits $866B Market Milestone (PR Newswire) +5.30%
Aug-25-25 07:00AM	New Evidence Published Supporting Use of DecisionDx-SCC Test in Guiding and Improving Treatment Pathway Decisions in NCCN High-Risk Cutaneous Squamous Cell Carcinoma (GlobeNewswire)
Aug-21-25 07:00AM	Castle Biosciences to Participate in Upcoming Investor Conferences (GlobeNewswire)
03:04AM	Loading…
Aug-05-25 03:04AM	Castle Biosciences Inc (CSTL) Q2 2025 Earnings Call Highlights: Navigating Revenue Challenges ... (GuruFocus.com) +32.83%
Aug-04-25 05:20PM	Castle Biosciences, Inc. (CSTL) Q2 Earnings and Revenues Surpass Estimates (Zacks)
04:05PM	Castle Biosciences Reports Second Quarter 2025 Results (GlobeNewswire)
Aug-01-25 05:11AM	New Strong Sell Stocks for August 1st (Zacks)
Jul-29-25 10:00AM	TG Therapeutics (TGTX) Earnings Expected to Grow: What to Know Ahead of Q2 Release (Zacks)
07:00AM	Castle Biosciences to Present at the Canaccord Genuity 45th Annual Growth Conference (GlobeNewswire)
Jul-28-25 10:00AM	Earnings Preview: Castle Biosciences, Inc. (CSTL) Q2 Earnings Expected to Decline (Zacks)
Jul-25-25 07:00AM	Castle Biosciences' Founder, President and CEO Derek Maetzold Named a Most Admired CEO by the Houston Business Journal (GlobeNewswire)
Jul-23-25 07:00AM	FDA Grants Breakthrough Device Designation to Castle Biosciences' DecisionDx-Melanoma Test (GlobeNewswire)
Jul-17-25 07:00AM	Castle Biosciences Honored with Multiple Top Workplaces Awards Recognizing the Company's Strong Culture (GlobeNewswire) -6.91%
07:00AM	Loading…
Jul-14-25 07:00AM	Castle Biosciences to Release Second Quarter 2025 Financial Results and Host Conference Call on Monday, Aug. 4, 2025 (GlobeNewswire)
Jun-19-25 07:00AM	Castle Biosciences Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) (GlobeNewswire)
Jun-16-25 04:30PM	Castle Biosciences Enters Collaboration and License Agreement with SciBase to Develop Diagnostic Tests for Dermatologic Diseases (GlobeNewswire)
Jun-11-25 07:00AM	Castle Biosciences' Chief Executive Officer Derek Maetzold to Participate in Panel Discussion During the 2025 BIO International Convention (GlobeNewswire)
Jun-04-25 07:00AM	Castle Biosciences' Founder, President and CEO Derek Maetzold Honored with Prestigious Lifetime Achievement Award by The American Business Awards (GlobeNewswire)
May-29-25 11:56PM	Castle Biosciences, Inc. (CSTL) Unveils Largest Real-World Melanoma Risk Study at ASCO 2025 (Insider Monkey)
04:30PM	New Data at ASCO 2025 Affirms DecisionDx-Melanoma's Ability to Improve Upon Staging-Based Risk Stratification and Predict Survival Outcomes (GlobeNewswire)
May-21-25 07:00AM	Castle Biosciences to Present at the 2025 Jefferies Global Healthcare Conference (GlobeNewswire)
May-09-25 07:00AM	Real-World Study Confirms Long-Term Performance of DecisionDx-UM for Metastatic Risk Stratification in Uveal Melanoma and Utility of PRAME Biomarker for Refining Risk When Considered with the DecisionDx-UM Class Result (GlobeNewswire)
May-07-25 07:00AM	Castle Biosciences Celebrates Skin Cancer Awareness Month (GlobeNewswire)
May-06-25 11:15AM	Q1 2025 Castle Biosciences Inc Earnings Call (Thomson Reuters StreetEvents) -11.36%
03:07AM	Castle Biosciences Inc (CSTL) Q1 2025 Earnings Call Highlights: Strong Revenue Growth Amidst ... (GuruFocus.com)
May-05-25 05:15PM	Castle Biosciences, Inc. (CSTL) Reports Q1 Loss, Tops Revenue Estimates (Zacks)
04:06PM	Castle Biosciences Reports First Quarter 2025 Results (GlobeNewswire)
04:05PM	Castle Biosciences to Acquire Previse (GlobeNewswire)
04:30PM	Loading…
May-02-25 04:30PM	New Data at DDW 2025 Further Demonstrates the TissueCypher Test's Ability to Identify Patients at Increased Risk for Developing Esophageal Cancer (GlobeNewswire)
09:30AM	Castle Biosciences Inc (CSTL) Q1 2025 Earnings Report Preview: What To Expect (GuruFocus.com)
Apr-30-25 05:00PM	New Study Shows Castle Biosciences' DecisionDx-Melanoma Test Outperforms Staging and CP-GEP in Identifying Patients at Low Risk of Sentinel Lymph Node Positivity (GlobeNewswire)
07:05AM	GSK (GSK) Q1 Earnings Surpass Estimates (Zacks)
Apr-28-25 07:00AM	DecisionDx -Melanoma Test Ordered More Than 200,000 Times for Patients Diagnosed with Cutaneous Melanoma (GlobeNewswire)
Apr-25-25 04:15PM	New Data at AACR Annual Meeting Highlights Use of DecisionDx -Melanoma to Identify Early-Stage Melanoma Patients at High Risk of Distant Metastasis (GlobeNewswire)
Apr-14-25 07:10PM	Castle Biosciences: Steady Revenue Stream, But Medicare Reimbursement Loss A Concern (Seeking Alpha) +5.83%
07:00AM	Castle Biosciences to Release First Quarter 2025 Financial Results and Host Conference Call on Monday, May 5, 2025 (GlobeNewswire)
Apr-08-25 07:00AM	Castle Biosciences Strengthens Commitment to Esophageal Cancer Awareness Through Collaborative Partnerships (GlobeNewswire)
Apr-07-25 07:00AM	Castle Biosciences Honored with a Top Workplaces USA Award for Fourth Consecutive Year (GlobeNewswire)
Apr-03-25 07:00AM	Publication of Data from Prospective, Multicenter Study Demonstrates Positive Survival Outcomes in Patients with Low-Risk Melanoma Who Avoided Sentinel Lymph Node Biopsy with Information from Castle Biosciences' DecisionDx-Melanoma Test (GlobeNewswire)
Apr-01-25 04:30PM	Castle Biosciences to Present New Data at EADO Supporting the Clinical Value of the DecisionDx -Melanoma Test in Guiding Risk-Aligned Management of Patients with Melanoma (GlobeNewswire)
Mar-28-25 04:15PM	Castle Biosciences' DecisionDx -SCC Data Earns Top Five Abstract at NCCN 2025, Shows Significantly Enhanced Risk Stratification Beyond Current Staging Within NCCN Risk Groups (GlobeNewswire)
Mar-07-25 07:00AM	New Data to be Presented at the 2025 American Academy of Dermatology (AAD) Annual Meeting Further Strengthens Evidence Supporting the Clinical Value of Castle Biosciences' Dermatology Portfolio (Business Wire)
Feb-28-25 11:11AM	Q4 2024 Castle Biosciences Inc Earnings Call (Thomson Reuters StreetEvents) -14.24%
02:37AM	Castle Biosciences Inc (CSTL) Q4 2024 Earnings Call Highlights: Record Revenue Growth and ... (GuruFocus.com)
Feb-27-25 06:15PM	Castle Biosciences, Inc. (CSTL) Surpasses Q4 Earnings and Revenue Estimates (Zacks)
04:05PM	Castle Biosciences Reports Fourth Quarter and Full-Year 2024 Results (Business Wire)
Feb-26-25 07:58AM	What To Expect From Castle Biosciences Inc (CSTL) Q4 2024 Earnings (GuruFocus.com)
Feb-25-25 04:30PM	Castle Biosciences to Participate in Upcoming Investor Conferences (Business Wire)
Feb-20-25 10:00AM	Castle Biosciences, Inc. (CSTL) Reports Next Week: Wall Street Expects Earnings Growth (Zacks)
09:55AM	Wall Street Analysts See a 50.79% Upside in Castle Biosciences (CSTL): Can the Stock Really Move This High? (Zacks)
Feb-12-25 04:30PM	Castle Biosciences to Share Data Reinforcing the Clinical Value of Its Dermatologic Portfolio of Gene Expression Profile Tests at the 22nd Annual Winter Clinical Dermatology Conference - Hawaii (Business Wire)
12:20PM	Surging Earnings Estimates Signal Upside for Castle Biosciences (CSTL) Stock (Zacks)
12:00PM	Castle Biosciences (CSTL) Upgraded to Buy: Here's Why (Zacks)
Feb-06-25 07:00AM	Castle Biosciences to Release Fourth Quarter and Full-Year 2024 Financial Results and Host Conference Call on Thursday, Feb. 27, 2025 (Business Wire)
Jan-29-25 09:55AM	Wall Street Analysts Think Castle Biosciences (CSTL) Could Surge 51.52%: Read This Before Placing a Bet (Zacks)
Jan-17-25 07:00AM	Castles Poster on DecisionDx-SCC Selected as a Late Breakers Top Five Finalist for the Akamai Award, Recognizing the Best Posters at Maui Derm Hawaii 2025 (Business Wire)
Jan-12-25 06:00PM	Castle Biosciences Announces Preliminary Unaudited Fourth Quarter and Full-Year 2024 Results (Business Wire)
Jan-06-25 11:15AM	Castle Biosciences gains New York state approval for Barretts oesophagus test (Medical Device Network)
07:00AM	Castle Biosciences Announces New York State Department of Health Approval of Its TissueCypher Barretts Esophagus Test (Business Wire)
Dec-24-24 08:10AM	Castle Biosciences reports preliminary data from atopic dermatitis test study (Medical Device Network)
Dec-23-24 07:00AM	Castle Biosciences Highlights Progress for its Pipeline Atopic Dermatitis Gene Expression Profile Test (Business Wire)
Dec-19-24 07:00AM	Castle Biosciences Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) (Business Wire)
Dec-16-24 09:55AM	Wall Street Analysts Believe Castle Biosciences (CSTL) Could Rally 42.02%: Here's is How to Trade (Zacks)
Dec-12-24 07:00AM	Independent Systematic Review and Meta-Analysis Attests to the Significant Risk Stratification Provided by Castle Biosciences DecisionDx-Melanoma Test, Contributing to Personalized Management of Patients with Melanoma (Business Wire)
Nov-20-24 07:00AM	Castle Biosciences to Present at the Piper Sandler 36th Annual Healthcare Conference (Business Wire)
Nov-19-24 07:00AM	Castle Biosciences Earns a Houston Chronicle Top Workplaces Award for the Fourth Consecutive Year (Business Wire)
Nov-08-24 08:50AM	Castle Biosciences (CSTL) Is a Great Choice for 'Trend' Investors, Here's Why (Zacks)
07:00AM	Castle Biosciences to Present New Data Highlighting the Clinical Performance of DecisionDx-Melanoma and MyPath Melanoma at the American Society of Dermatopathology 61st Annual Meeting (Business Wire)
Nov-07-24 12:00PM	Castle Biosciences (CSTL) Upgraded to Strong Buy: Here's Why (Zacks)
07:52AM	Castle boasts melanoma tests capacity to reduce unnecessary testing (Medical Device Network)
07:00AM	Castle Biosciences Surpasses 25,000 Test Reports Delivered for its TissueCypher Barretts Esophagus Test (Business Wire)
Nov-06-24 07:00AM	Use of Castle Biosciences DecisionDx-Melanoma Test Significantly Reduces Unnecessary SLNB Procedures, Latest Findings from Prospective, Multicenter DECIDE Study Presented at Dermato-Onco2024 (Business Wire)
06:45AM	Castle Biosciences price target raised to $39 from $37 at Baird (TipRanks)
06:25AM	Castle Biosciences price target raised to $36 from $28 at KeyBanc (TipRanks)
Nov-05-24 02:00PM	Castle Biosciences Inc (CSTL) Q3 2024 Earnings Call Highlights: Strong Revenue Growth and ... (GuruFocus.com) -7.40%
Nov-04-24 05:50PM	Castle Biosciences, Inc. (CSTL) Tops Q3 Earnings and Revenue Estimates (Zacks)
04:05PM	Castle Biosciences Reports Third Quarter 2024 Results (Business Wire)
Nov-01-24 09:15AM	Castle Biosciences, Inc. (CSTL) Hit a 52 Week High, Can the Run Continue? (Zacks)
09:05AM	Castle Biosciences Inc (CSTL) Q3 2024 Earnings Report Preview: What To Expect (GuruFocus.com)
Oct-29-24 04:30PM	Castle Biosciences Presents Award-Winning Abstract at ACG 2024 Demonstrating Ability of Its TissueCypher Test to Significantly Reduce Healthcare Costs Associated with the Management of Barretts Esophagus Patients (Business Wire)
Oct-28-24 07:00AM	Castle Biosciences to Participate in Upcoming Investor Conferences (Business Wire)
Oct-23-24 08:50AM	Here's Why Momentum in Castle Biosciences (CSTL) Should Keep going (Zacks)
Oct-22-24 12:00PM	Castle Biosciences, Inc. (CSTL) is a Great Momentum Stock: Should You Buy? (Zacks)
Oct-20-24 05:00AM	Castle Biosciences Presents New Data at ASDS from Prospective, Multicenter CONNECTION Study Supporting Use of DecisionDx-Melanoma to Guide SLNB Decisions in T1a Tumors with High-Risk Features and T1b Tumors (Business Wire)
Oct-16-24 07:00AM	Recent Publications Affirm the Value of Gene Expression Profile Testing in Guiding a Definitive Diagnosis and Clinical Decision-Making in Melanocytic Lesions of Uncertain Malignant Potential (Business Wire)
Oct-15-24 09:15AM	Castle Biosciences, Inc. (CSTL) Soars to 52-Week High, Time to Cash Out? (Zacks)
07:30AM	Castle Biosciences price target raised to $40 from $35 at BTIG (TipRanks)
04:47AM	Strength Seen in Castle Biosciences (CSTL): Can Its 9.4% Jump Turn into More Strength? (Zacks)
Oct-14-24 07:00AM	Castle Biosciences to Release Third Quarter 2024 Financial Results and Host Conference Call on Monday, Nov. 4, 2024 (Business Wire) +9.42%
Oct-11-24 07:00AM	Castle Biosciences to Support the 71st Annual Montagna Symposium on the Biology of the Skin (Business Wire) +10.64%
Oct-09-24 03:58PM	Castle Biosciences Inc (CSTL) Q2 2024 Earnings Call Highlights: Record Revenue Growth and ... (GuruFocus.com)
07:00AM	New Prospective, Multicenter Study Presented at SMR Demonstrates Castle Biosciences DecisionDx-Melanoma Test Provides Significant Risk Prediction for Patients with Cutaneous Melanoma, Adding Value to Current Stage-Based Treatment Pathway Decisions (Business Wire)
Oct-07-24 12:00PM	Castle Biosciences (CSTL) Upgraded to Strong Buy: Here's What You Should Know (Zacks)
Oct-02-24 07:00AM	Castle Biosciences Hosts Groundbreaking Ceremony at Site of New Corporate Headquarters in Friendswood, Texas (Business Wire)
Sep-27-24 05:15PM	New Data at ASTRO 2024 Shows Castle Biosciences DecisionDx-SCC Test Provides More Precise Risk Stratification Than BWH Staging Alone to Guide Intensified Treatment for Immune Suppressed Patients with High-Risk Cutaneous Squamous Cell Carcinoma (Business Wire)
Sep-23-24 07:00AM	New Data at AFS 2024 Demonstrates the Strength of Castle Biosciences TissueCypher Test in Independently Predicting Risk of Developing Esophageal Cancer, Guiding Risk-Aligned Management Decisions for Patients with Barretts Esophagus (Business Wire)
Sep-16-24 07:00AM	Castle Biosciences Chief Operating Officer Kristen Oelschlager Named Arizona Bioscience Leader of the Year (Business Wire)
Sep-11-24 07:00AM	DecisionDx-Melanoma Can Identify Melanoma Patients with Low Risk of Sentinel Lymph Node Positivity Who May Safely Forego Biopsy Surgery, New Independent Study Affirms (Business Wire) +5.90%

Castle Biosciences, Inc.is a molecular diagnostics company offering innovative test solutions to aid clinicians in the diagnosis and treatment of dermatologic cancers, barrett's esophagus, uveal melanoma, and in the treatment of mental health conditions. The firm offers DecisionDx-Melanoma, a proprietary multi-gene expression profile (GEP) test that predicts the risk of metastasis and recurrence for patients diagnosed with invasive cutaneous melanoma. It also markets DecisionDx-UM, Decision Dx DiffDx-Melanoma, DecisonDx-CMSeq, DecisionDx-SCC, DecsionDx-UMSeq, and DecisonDX-PRAME. The company was founded by Derek J. Maetzold in September 2007 and is headquartered in Friendswood, TX.

Insider Trading	Relationship	Date	Transaction	Cost	#Shares	Value ($)	#Shares Total	SEC Form 4
MAETZOLD DEREK J	Pres. & Chief Exec. Officer	Sep 02 '25	Sale	23.93	1,339	32,042	67,005	Sep 04 04:04 PM
Oelschlager Kristen M	Chief Operating Officer	Aug 27 '25	Sale	22.02	12,677	279,135	141,116	Aug 29 04:04 PM
Oelschlager Kristen M	Chief Operating Officer	Aug 27 '25	Sale	21.69	18,007	390,572	153,793	Aug 29 04:04 PM
Kristen M. Oelschlager	Officer	Aug 27 '25	Proposed Sale	21.35	18,007	384,449		Aug 27 06:15 PM
Kristen M. Oelschlager	Officer	Aug 27 '25	Proposed Sale	21.35	25,355	541,329		Aug 27 04:56 PM
MAETZOLD DEREK J	Pres. & Chief Exec. Officer	Aug 15 '25	Sale	20.04	1,339	26,834	68,344	Aug 19 04:04 PM
Derek Maetzold	Officer	Aug 15 '25	Proposed Sale	20.09	4,017	80,702		Aug 15 05:19 PM
MAETZOLD DEREK J	Pres. & Chief Exec. Officer	Aug 13 '25	Sale	19.50	43,019	839,043	69,683	Aug 15 04:14 PM
Derek Maetzold	Officer	Aug 13 '25	Proposed Sale	19.41	43,019	834,999		Aug 13 05:30 PM
MAETZOLD DEREK J	Pres. & Chief Exec. Officer	Aug 08 '25	Option Exercise	0.00	66,991	0	136,674	Aug 12 04:32 PM
Stokes Frank	Chief Financial Officer	Aug 08 '25	Option Exercise	0.00	9,744	0	53,072	Aug 12 04:31 PM
Oelschlager Kristen M	Chief Operating Officer	Aug 08 '25	Option Exercise	0.00	10,640	0	174,604	Aug 12 04:31 PM
Juvenal Tobin W	Chief Commercial Officer	Aug 08 '25	Option Exercise	0.00	10,640	0	88,821	Aug 12 04:30 PM
MAETZOLD DEREK J	Pres. & Chief Exec. Officer	Jun 27 '25	Sale	20.30	17,632	357,930	3,615	Jul 01 04:05 PM
MAETZOLD DEREK J	Pres. & Chief Exec. Officer	Jun 27 '25	Sale	20.30	4,944	100,363	69,683	Jul 01 04:05 PM
Derek Maetzold	Officer	Jun 27 '25	Proposed Sale	20.35	16,932	344,566		Jun 27 06:11 PM
MAETZOLD DEREK J	Pres. & Chief Exec. Officer	Apr 21 '25	Sale	21.52	4,408	94,851	4,275	Apr 23 04:08 PM
MAETZOLD DEREK J	Pres. & Chief Exec. Officer	Apr 21 '25	Sale	21.52	1,236	26,596	74,627	Apr 23 04:08 PM
MAETZOLD DEREK J	Pres. & Chief Exec. Officer	Apr 09 '25	Sale	20.22	3,647	73,739	4,440	Apr 10 04:07 PM
MAETZOLD DEREK J	Pres. & Chief Exec. Officer	Apr 09 '25	Sale	20.22	1,023	20,684	75,863	Apr 10 04:07 PM
MAETZOLD DEREK J	Pres. & Chief Exec. Officer	Apr 08 '25	Sale	20.03	761	15,243	4,577	Apr 10 04:07 PM
MAETZOLD DEREK J	Pres. & Chief Exec. Officer	Apr 08 '25	Sale	20.03	213	4,266	76,886	Apr 10 04:07 PM
Derek Maetzold	Officer	Apr 08 '25	Proposed Sale	18.60	16,932	314,935		Apr 08 04:56 PM
MAETZOLD DEREK J	Pres. & Chief Exec. Officer	Mar 26 '25	Sale	20.30	4,408	89,482	4,605	Mar 28 04:07 PM
MAETZOLD DEREK J	Pres. & Chief Exec. Officer	Mar 26 '25	Sale	20.30	1,236	25,091	77,099	Mar 28 04:07 PM
MAETZOLD DEREK J	Pres. & Chief Exec. Officer	Mar 07 '25	Sale	20.12	22,639	455,426	80,465	Mar 11 04:07 PM
MAETZOLD DEREK J	Pres. & Chief Exec. Officer	Mar 07 '25	Sale	20.12	4,408	88,674	4,770	Mar 11 04:07 PM
MAETZOLD DEREK J	Pres. & Chief Exec. Officer	Mar 10 '25	Sale	19.52	2,130	41,573	78,335	Mar 11 04:07 PM
Derek Maetzold	Officer	Mar 07 '25	Proposed Sale	20.21	34,821	703,732		Mar 07 04:57 PM
Derek Maetzold	Officer	Mar 04 '25	Proposed Sale	22.23	5,687	126,422		Mar 04 05:28 PM
Stokes Frank	Chief Financial Officer	Feb 20 '25	Sale	26.70	8,046	214,828	35,319	Feb 24 04:23 PM
BRADBURY DANIEL	Director	Feb 05 '25	Sale	28.17	7,867	221,637	0	Feb 07 04:12 PM
Daniel Bradbury	Officer	Feb 05 '25	Proposed Sale	28.12	7,867	221,220		Feb 05 04:25 PM
MAETZOLD DEREK J	Pres. & Chief Exec. Officer	Jan 13 '25	Sale	28.03	1,579	44,262	5,104	Jan 15 04:57 PM
MAETZOLD DEREK J	Pres. & Chief Exec. Officer	Jan 13 '25	Sale	28.03	986	27,641	80,818	Jan 15 04:57 PM
BRADBURY DANIEL	Director	Jan 06 '25	Sale	29.14	7,867	229,226	1,425	Jan 08 06:19 PM
MAETZOLD DEREK J	Pres. & Chief Exec. Officer	Jan 06 '25	Sale	29.62	4,343	128,637	5,291	Jan 08 06:18 PM
MAETZOLD DEREK J	Pres. & Chief Exec. Officer	Jan 06 '25	Sale	29.62	2,715	80,412	82,047	Jan 08 06:18 PM
MAETZOLD DEREK J	Pres. & Chief Exec. Officer	Jan 07 '25	Sale	30.14	388	11,694	5,254	Jan 08 06:18 PM
MAETZOLD DEREK J	Pres. & Chief Exec. Officer	Jan 07 '25	Sale	30.14	243	7,324	81,804	Jan 08 06:18 PM
Juvenal Tobin W	Chief Commercial Officer	Jan 06 '25	Sale	30.00	2,230	66,900	69,943	Jan 08 06:17 PM
TOBIN JUVENAL	Officer	Jan 06 '25	Proposed Sale	28.61	2,230	63,800		Jan 06 04:29 PM
MAETZOLD DEREK J	Pres. & Chief Exec. Officer	Dec 17 '24	Sale	28.34	9,364	265,358	84,762	Dec 19 04:39 PM
MAETZOLD DEREK J	Pres. & Chief Exec. Officer	Dec 13 '24	Sale	28.64	13,485	386,209	105,185	Dec 17 04:21 PM
MAETZOLD DEREK J	Pres. & Chief Exec. Officer	Dec 16 '24	Sale	28.83	11,059	318,864	94,126	Dec 17 04:21 PM
MAETZOLD DEREK J	Pres. & Chief Exec. Officer	Dec 13 '24	Sale	28.64	1,579	45,223	5,702	Dec 17 04:21 PM
Derek Maetzold	Officer	Dec 13 '24	Proposed Sale	28.87	48,303	1,394,508		Dec 13 05:00 PM
MAETZOLD DEREK J	Pres. & Chief Exec. Officer	Dec 05 '24	Sale	31.35	3,155	98,916	5,852	Dec 09 05:09 PM
MAETZOLD DEREK J	Pres. & Chief Exec. Officer	Dec 05 '24	Sale	31.35	1,972	61,826	85,748	Dec 09 05:09 PM
BRADBURY DANIEL	Director	Dec 03 '24	Sale	30.98	7,867	243,693	2,850	Dec 05 04:28 PM
Daniel Bradbury	Officer	Dec 03 '24	Proposed Sale	30.78	15,734	484,293		Dec 03 05:14 PM
Stokes Frank	Chief Financial Officer	Nov 15 '24	Sale	29.93	6,923	207,217	30,823	Nov 19 04:04 PM
MAETZOLD DEREK J	Pres. & Chief Exec. Officer	Nov 12 '24	Sale	34.15	3,155	107,743	6,151	Nov 14 06:21 PM
MAETZOLD DEREK J	Pres. & Chief Exec. Officer	Nov 12 '24	Sale	34.15	1,972	67,344	87,720	Nov 14 06:21 PM
Stokes Frank	Officer	Nov 15 '24	Proposed Sale	31.48	6,923	217,936		Nov 14 01:39 PM
Juvenal Tobin W	Chief Commercial Officer	Nov 05 '24	Option Exercise	3.38	3,507	11,854	57,685	Nov 07 04:12 PM
Juvenal Tobin W	Chief Commercial Officer	Nov 05 '24	Sale	35.56	3,507	124,709	54,178	Nov 07 04:12 PM
MAETZOLD DEREK J	Pres. & Chief Exec. Officer	Nov 04 '24	Sale	32.54	3,155	102,657	6,450	Nov 06 04:21 PM
MAETZOLD DEREK J	Pres. & Chief Exec. Officer	Nov 04 '24	Sale	32.54	1,972	64,163	89,692	Nov 06 04:21 PM
Juvenal Tobin W	Chief Commercial Officer	Nov 01 '24	Option Exercise	3.38	1,100	3,718	57,278	Nov 05 04:33 PM
Juvenal Tobin W	Chief Commercial Officer	Nov 01 '24	Sale	35.39	3,100	109,709	54,178	Nov 05 04:33 PM
BRADBURY DANIEL	Director	Nov 01 '24	Sale	34.73	7,867	273,251	4,275	Nov 05 04:32 PM
Derek Maetzold	Officer	Nov 04 '24	Proposed Sale	33.64	15,381	517,417		Nov 04 05:34 PM
TOBIN JUVENAL	Officer	Nov 01 '24	Proposed Sale	34.67	12,000	416,040		Nov 01 04:49 PM
MAETZOLD DEREK J	Pres. & Chief Exec. Officer	Oct 14 '24	Sale	32.27	3,155	101,821	6,749	Oct 16 04:34 PM
MAETZOLD DEREK J	Pres. & Chief Exec. Officer	Oct 14 '24	Sale	32.27	1,972	63,642	91,664	Oct 16 04:34 PM
MAETZOLD DEREK J	Pres. & Chief Exec. Officer	Oct 08 '24	Sale	30.27	1,576	47,704	7,048	Oct 10 04:22 PM
MAETZOLD DEREK J	Pres. & Chief Exec. Officer	Oct 08 '24	Sale	30.27	986	29,845	93,636	Oct 10 04:22 PM
BRADBURY DANIEL	Director	Oct 07 '24	Sale	29.44	7,867	231,628	5,700	Oct 09 04:30 PM
MAETZOLD DEREK J	Pres. & Chief Exec. Officer	Oct 04 '24	Sale	28.73	1,579	45,371	7,197	Oct 08 04:48 PM
MAETZOLD DEREK J	Pres. & Chief Exec. Officer	Oct 04 '24	Sale	28.73	986	28,332	94,622	Oct 08 04:48 PM
Daniel Bradbury	Officer	Oct 07 '24	Proposed Sale	29.52	15,734	464,468		Oct 07 05:33 PM

open in yahoo | open in reuters | open in marketwatch | open in google | open in EDGAR

CSTL

Castle Biosciences Inc

Upgrade your FINVIZ experience